Pharmacogenetics of alcohol addiction: current perspectives

Figures & data

Table 1 The statistically significant associations between the individual drug response and genetic polymorphism

Drug	Gene	Polymorphism	Brief Description of the Results	Reference
Disulfiram	ANKK1	rs1800497	Increase the efficacy of the therapy on patients with coccaine addiction. There is no data in patients with AUD.	^Citation16
Disulfiram	DRD2	rs2283265
Naltrexone	OPRM1	118A>G	Greater efficacy of naltrexone among the carriers of this polymorphism	^Citation19, ^Citation25,Citation26,Citation27,Citation28,Citation29,Citation30,Citation31
Naltrexone	OPRK1	rs997917	Greater naltrexone-induced blunting of alcohol stimulation and craving	^Citation43
Naltrexone	OPRD1	rs4654327
Acamprosate	GATA4	rs13273672	Decrease the duration of remission	^Citation53
Acamprosate	GRIN2B	rs2058878	Increase the duration of remission	^Citation56
Topiramate	GRIK1	rs2832407	Decrease the duration of remission	^Citation77,Citation78,Citation79,Citation80
Ondansetron	HTR3A	rs1150226, rs1176713	Increase the efficacy of ondansetron (reduced drinking)	^Citation90
Ondansetron	HTR3B	rs17614942
Diazepam	CYP2C19	c.681G>A, c.636G>A	Reduced clearance	^Citation108,Citation109,Citation110

Spellicy CJ, Kosten TR, Hamon SC, Harding MJ, Nielsen DA. ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse. Pharmacogenet Genomics. 2013;23(7):333–340. doi:10.1097/FPC.0b013e328361c39d23635803

 PubMed Web of Science ®Google Scholar

Anton RF, Oroszi G, O’Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65(2):135–144. doi:10.1001/archpsyc.65.2.13518250251

 PubMed Web of Science ®Google Scholar

Chamorro AJ, Marcos M, Miron-Canelo JA, Pastor I, Gonzalez-Sarmiento R, Laso FJ. Association of micro-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol. 2012;17(3):505–512. doi:10.1111/j.1369-1600.2012.00442.x22515274

 PubMed Web of Science ®Google Scholar

Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28(8):1546–1552. doi:10.1038/sj.npp.130021912813472

 PubMed Web of Science ®Google Scholar

Kranzler HR, Armeli S, Covault J, Tennen H. Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. Addict Biol. 2013;18(1):193–201. doi:10.1111/j.1369-1600.2012.00471.x22784013

 PubMed Web of Science ®Google Scholar

McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr. Genetic moderators of naltrexone’s effects on alcohol cue reactivity. Alcohol Clin Exp Res. 2006;30(8):1288–1296. doi:10.1111/j.1530-0277.2006.00156.x16899031

 PubMed Web of Science ®Google Scholar

Kim SG, Kim CM, Choi SW, et al. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl). 2009;201(4):611–618. doi:10.1007/s00213-008-1330-518795264

 PubMed Web of Science ®Google Scholar

Ooteman W, Naassila M, Koeter MW, et al. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009;14(3):328–337. doi:10.1111/j.1369-1600.2009.00159.x19523047

 PubMed Web of Science ®Google Scholar

Chen AC, Morgenstern J, Davis CM, Kuerbis AN, Covault J, Kranzler HR. Variation in mu-opioid receptor gene (OPRM1) as a moderator of naltrexone treatment to reduce heavy drinking in a high functioning cohort. J Alcohol Drug Depend. 2013;1(1):101.24729984

 PubMedGoogle Scholar

Ashenhurst JR, Bujarski S, Ray LA. Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. Pharmacol Biochem Behav. 2012;103(2):253–259. doi:10.1016/j.pbb.2012.08.01922954510

 PubMed Web of Science ®Google Scholar

Kiefer F, Witt SH, Frank J, et al. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. Pharmacogenomics J. 2011;11(5):368–374. doi:10.1038/tpj.2010.5120585342

 PubMed Web of Science ®Google Scholar

Karpyak VM, Biernacka JM, Geske JR, et al. Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Transl Psychiatry. 2014;7(4):e462.

 Google Scholar

Morley KC, Kranzler HR, Luquin N, et al. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study). Trials. 2018;19(1):443. doi:10.1186/s13063-018-2824-z30115121

 PubMed Web of Science ®Google Scholar

Kranzler HR, Armeli S, Wetherill R, et al. Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking. Addict Biol. 2016;21(2):450–459. doi:10.1111/adb.1220725496338

 PubMed Web of Science ®Google Scholar

Miranda R Jr, MacKillop J, Monti PM, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res. 2008;32(3):489–497. doi:10.1111/j.1530-0277.2007.00592.x18215213

 PubMed Web of Science ®Google Scholar

Ray LA, Miranda R Jr, MacKillop J, et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009;17(2):122–129. doi:10.1037/a001570019331489

 PubMed Web of Science ®Google Scholar

Johnson BA, Seneviratne C, Wang XQ, Ait-Daoud N, Li MD. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron. Am J Psychiatry. 2013;170(9):1020–1031. doi:10.1176/appi.ajp.2013.1209116323897038

 PubMed Web of Science ®Google Scholar

Sohn DR, Kusaka M, Ishizaki T, et al. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther. 1992;52(2):160–169. doi:10.1038/clpt.1992.1251505151

 PubMed Web of Science ®Google Scholar

Zhang YA, Reviriego J, Lou YQ, Sjöqvist F, Bertilsson L. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects. Clin Pharmacol Ther. 1990;48(5):496–502. doi:10.1038/clpt.1990.1852225709

 PubMed Web of Science ®Google Scholar

Wan J, Xia H, He N, Lu YQ, Zhou HH. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Br J Clin Pharmacol. 1996;42(4):471–474. doi:10.1111/j.1365-2125.1996.tb00010.x8904619

 PubMed Web of Science ®Google Scholar